lysyl-aspartyl-glutamyl-leucine has been researched along with Androgen-Independent Prostatic Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, M; Delie, F; Petignat, P | 1 |
1 other study(ies) available for lysyl-aspartyl-glutamyl-leucine and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78.
Topics: Antibodies; Apoptosis; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Male; Molecular Targeted Therapy; Nanoparticles; Oligopeptides; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Protein Sorting Signals; Signal Transduction | 2013 |